新辅助化疗对即刻组织扩张器乳房重建中植入物丢失的影响
新辅助化疗组病理学组织扩张器丢失率显著更高(14% vs 7%,P=0.032),回归分析显示新辅助化疗使全因和病理学丢失率增加17%(P<0.05)。
要点
- 新辅助化疗是即刻组织扩张器重建后组织扩张器丢失的独立危险因素。
- 新辅助化疗组病理学组织扩张器丢失率14%,未化疗组7%(P=0.032)。
- 伤口、血清肿和感染并发症两组间无统计学显著差异。
核心结论
- 新辅助化疗是即刻组织扩张器乳房重建后组织扩张器丢失的独立危险因素。
研究设计与样本
- 单中心回顾性综述,纳入2017至2024年210例患者共319侧乳房组织扩张器乳房重建。
主要发现
- 新辅助化疗组全因组织扩张器丢失率18%,未化疗组11%。
- 新辅助化疗组病理学组织扩张器丢失率14%,未化疗组7%(P=0.032)。
- 回归分析显示新辅助化疗使全因和病理学组织扩张器丢失率增加17%(P<0.05)。
- 伤口、血清肿和感染并发症两组间无统计学显著差异。
临床怎么用
- 对接受新辅助化疗的患者行即刻组织扩张器乳房重建时,应充分告知组织扩张器丢失风险增高。
- 围手术期需加强组织扩张器丢失的风险评估与监测。
局限性
- 单中心回顾性设计可能引入选择偏倚。
- 未进一步分析辅助治疗、植入物因素及具体化疗药物对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implant-based reconstruction represents the most common method of breast reconstruction today. Many surgeons approach implant-based breast reconstruction in 2 stages, with the first stage being placement of a tissue expander at the time of mastectomy. Neoadjuvant chemotherapy can have systemic effects that may place patients at risk for TE/implant loss, infection, wound, and other complications. METHODS: A retrospective review of all cases of TE breast reconstruction at a single institution between 2017 and 2024 was performed. A total of 210 patients, representing 319 total breasts that underwent reconstruction, met the inclusion criteria. Sixty-five patients underwent neoadjuvant chemotherapy and 145 did not. Patients were separated into neoadjuvant chemotherapy (NACT) and nonneoadjuvant chemotherapy (non-NACT) cohorts. Primary outcomes of TE loss, wound, infection, and seroma were analyzed. Regression analysis was performed, matching patients for known risk factors. RESULTS: The rate of all-cause TE loss in patients who underwent NACT was 18%, and 11% for patients who did not. The rate of pathologic TE loss was significantly higher at 14% in patients who underwent NACT and 7% in patients who did not undergo NACT ( P =0.032). On regression analysis, neoadjuvant chemotherapy increased the rate of all-cause and pathologic TE loss by 17% ( P <0.05). There were no statistically significant differences in wound, seroma, and infection. CONCLUSIONS: In this study, neoadjuvant chemotherapy is an independent risk factor for TE loss after immediate tissue expander-based breast reconstruction. Further analysis of adjuncts, implant factors, and specific chemotherapeutic agents is needed.
引用
- DeVito RG, Wen E, Wehelie HM, et al. The Effect of Neoadjuvant Chemotherapy on Implant Loss in Immediate Tissue Expander-Based Breast Reconstruction. Ann Plast Surg. 2026. PMID: 41811191. doi:10.1097/SAP.0000000000004707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。